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Multilineage-differentiating stress-enduring (Muse) cells were discovered in 2010 as
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a subpopulation of mesenchymal stroma cells (MSCs). Muse cells can self-renew and
tolerate severe culturing conditions. These cells can differentiate into three lineage
cells spontaneously or in induced medium but do not form teratoma in vitro or
in vivo. Central nervous system (CNS) diseases, such as intracerebral hemorrhage
(ICH), cerebral infarction, and spinal cord injury are normally disastrous. Despite
numerous therapy strategies, CNS diseases are difficult to recover. As a novel kind
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of pluripotent stem cells, Muse cells have shown great regeneration capacity in many
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animal models, including acute myocardial infarction, hepatectomy, and acute cerebral
ischemia (ACI). After injection into injury sites, Muse cells survived, migrated, and
differentiated into functional neurons with synaptic junctions to local neurons and
contributed to recovery of function. Furthermore, Muse cell differentiation did
not need to be induced pre-transplantation and no tumors were observed posttransplantation. The Muse cell population is promising and may lead to a revolution
in regenerative medicine. This review focuses on recent advances regarding the
Muse cells therapies in Neurorestoratology and discusses future perspectives in
this field.

1

Introduction

Multilineage-differentiating stress-enduring (Muse)
cells are a novel pluripotent stem cell population first
described by Professor Mari Dezawa et al. in 2010 [1].
They are a subtype of mesenchymal stromal cells
(MSCs) that express the state-specific embryonic
antigen 3 (SSEA3). Muse cells have the characteristics
of stem cells. Firstly, Muse cells can self-renew. Through
limiting dilution, Kuroda et al. [2] and Wakao et al. [3]
seeded 50 single Muse cells into a 96-well plate coated
by poly-HEMA. Muse cell clusters formed after 7–10
days and were stained SSEA3+. After that, the clusters
were transferred into an uncoated plate. The cells
attached to the bottom of the plate and extended.
Corresponding author: Xijing He, E-mail: xijing_h@vip.tom.com

The single cluster culturing cycle was repeatable. To
keep the stemness, the culturing medium consisted
of DMEM-low glucose (Gibco, 10567-014), 10% FBS
(Hyclone, vol/vol), 2 mM GlutaMAX (Gibco), 1 ng/ml
bFGF, 0.1 mg/ml kanamycin [2]. Secondly, Muse cells
can differentiate into endodermal-, ectodermal- and
mesodermal-lineage cells spontaneously in vitro or
through induction [1, 4, 5]. After 10–14 days of culturing
in gelatin-coated dishes, Muse cell clusters were NF+
and MAP2+ (ectoderm marker), SMA+ and Desmin+
(mesoderm markers), and CK7+ and α-FP+ (entoderm
markers) [2]. Another study showed that the rates of
spontaneous Muse cell differentiation to endodermal,
ectodermal, and mesodermal cells were 20%, 22%
and 23%, respectively [6]. When Muse cells received
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induction factors in different specific media in vitro,
98% of cells were Osteocalcin+ (osteocyte, mesoderm)
[2], 98% were red oil+ (adipocyte, mesoderm) [2],
90% were α-FP+ (hepatocyte, entoderm) [2], 90% were
MAP-2+ (Neuron, ectoderm) [2], and 43.1 ± 17.1% were
GP100+ (melanocyte, ectoderm) [7, 8]. When induced
Muse cell cultures were transplanted in vivo, cells
differentiated into adipocytes, skeletal muscle cells,
myocardial cells, biliary epithelial cells, glomerular
cells, glomerular endothelial cells, melanocytes and
neurons [8–16].

2

Characteristics of Muse cells

Muse cells own five special characteristics beyond
their basic stem cell qualities.
Firstly, Muse cells are stress enduring. Muse cells
survived in 0.5% trypsin for up to 16 hours [1]. They
also survived in a severe hypoxic environment without
fetal calf serum at 4 °C [17]. Researchers have used
severe culturing conditions to isolate and purify Muse
cells. Further gene analysis showed that the expressions
of CXCL2, ALDH1A2, and SOD2 were higher in Muse
cells than in non-Muse cells [6, 18, 19].
Secondly, Muse cells do not form teratomas in vivo
after the transplantation. The telomerase activity of
Muse cells is as low as zero [10]. Gene analysis showed
that CDH1 was overexpressed and alpha-6 integrin
(ITGA6) and Lin28 were down-regulated in Muse
cells [4, 6, 20, 21]. Animal studies in the testis of
severe combined immunodeficient mice (SCID) and
myocardial infarction sites of rabbits demonstrated
that injected Muse cells did not form tumors 6 months
post-injection [1, 4, 22]. Moreover, Muse cells are a
subpopulation of MSCs, which have been safely
transplanted in basic and clinical studies [23, 24].
Thirdly, Muse cells can autonomously home to
injured tissue. In the acute injury period, the level of
sphingosine monophosphate (S1P) was significantly
higher. But once the S1PR2 receptor antagonist, JET-013,
was administrated, the S1P-S1PR2 axis was blocked. In
this case, Muse cells did not show the homing function.
However, non-Muse cells still migrated slightly as
before. Furthermore, if the S1PR2 gene was knocked
out in Muse cells, they would lose the homing feature.
These results suggest that the S1P-S1PR2 axis is the
mechanism for Muse cell homing to lesion areas [22].
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Fourthly, Muse cells can be transplanted via allograft
without rejection from the host organism. Although
autologous cell transplantation is the safest method, it
takes 3–4 weeks to prepare cells, such as mesenchymal
stromal cells isolated and cultured from adipose tissue.
For strokes, spinal cord injuries and other acute central
nervous system injuries, cell therapies are best if
carried out before formation of glial scars. Muse cells
make this timeline possible [22].
Fifthly, Muse cells do not need to receive any
gene editing before transplantation, unlike induced
pluripotent stem cells (iPSCs), which need to be
induced by the transcription of factors Oct3/4, Sox2,
Klf4 and c-Myc [25]. However, the iPSCs would form
teratoma at 8–12 weeks after injected in vivo, while
Muse cells would not [4, 5, 26].
Distribution of Muse cells in the body
Muse cells were first discovered in the bone marrow,
and subsequent researches showed the presence of
Muse cells in the adipose tissue, dermis, and the
umbilical cord [3–5]. Because Muse cells were initially
considered to reside in mesenchymal tissues, the
percentage of Muse cells in the human bone marrow
is assumed to be around 0.01%–0.03% of the mononucleated cell fraction [1]. Muse cells also exist in
the peripheral blood at the proportion of 0.01%–0.2%
of the mononuclear fraction [27]. But the bone marrow
is directly connected to the peripheral blood, so
Muse cells in blood should be from the bone marrow.
Moreover, Muse cells also distribute to the connective
tissue of every organ, which has been demonstrated
in the dermis, spleen, pancreas, trachea, umbilical
cord, adipose tissue, and synovial membrane, but the
percentage is as sparse as 0.01%–3% [5, 28, 29]. Muse
cells are even found in the pia mater and arachnoid of
the brain (unpublished data by Mari Dezawa [30]).
When used in preclinical research, millions of
purified Muse cells are needed to meet the transplantation standards. The most popular isolation method
is fluorescence-activated cell sorting (FACS) [2]. Briefly,
it amplificated the MSC cells in adhesion culture and
got the cell suspension. Then it stained the cells with
anti-SSEA3 antibody and the fluorescent probe-labeled
secondary antibody. Finally, it isolated Muse cells by
FACS. Researchers also have used severe culturing
conditions to isolate and purify Muse cells, such as
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long-time trypsin [1], peroxide hydrogen or UV
irradiation [28], low oxygen and temperature [6]. But
personally, the isolated Muse cells may change their
characteristics under the severe culture stress. And
two published studies are involved in magnetically
activated cell sorting (MACS), but their isolation rate
were only 77.1% and 71.3% [15, 31].

3

3.1

Preclinical research of Muse cells in
Neurorestoratology
Muse cells treated glioma

Herpes simplex virus thymidine kinase (HSVtk) combined with Ganciclovir (GCV) is the most popular
treatment in the research of glioma [32]. Hiroki Namba’s
team [16] transplanted Muse-tk cells (HSVtk-IRES2EGFP-Muse cells) and U87-luc glioma cells together
into the brain of SCID mice, and GCV was administrated
by intraperitoneal injection (IP). Results showed that
mice survived for 100 days when the transplanted
cells’ ratio was 1:32 (Muse-tk cells: U87-luc cells) and no
glioma was observed in immunohistology staining.
On the other hand, if U87-luc cells were injected into
the SCID mice brain 7 days before the Muse-tk cells’
transplantation and GCV administration, all the SCID
mice died in 60 days in the blank control and GCV
administration-only groups. However, all the mice
survived 200 days in the Muse-tk/GCV group, and no
glioma was observed. The cell migration experiment
in vitro showed that the U87-luc cells-conditioned
medium could attract Muse-tk cells to migrate but
Non-Muse-tk did not. This study demonstrated that
intracranial injection of Muse-tk combined with GCV
IP was safe and effective in SCID glioma treatment.
3.2

Muse cells treated stroke

Mari Dezawa, the first to describe Muse cells,
demonstrated that human Muse cells reconstructed
neuronal circuity in subacute lacunar stroke SCID
mice [15]. In the study, stroke was induced in SCID
mice using the stroke model. After two weeks, Muse
cells from human bone marrow stromal cells were
transplanted into the local stroke area. The results
showed that 28% of injected Muse cells survived 8
weeks later, and the positive markers were NeuN
(neuron, 62%), MAP-2 (neuron, 30%) and GST-pi

(oligodendrocyte, 12%). Dextran tracer was used
to label Muse cells, demonstrating that Muse cells
reconstructed synaptic connections with host neurons.
Incredibly, the nerve fibers derived from Muse cells
surpassed the decussation level of the pyramid, crossed
to the offside pyramidal tract, and descended to the
level of the second cervical spinal cord. In the cylinder
function test, the score of the Muse cell transplantation
group was significantly higher than that of the nonMuse cells group. 10 months after transplantation,
the human specific Alu gene sequence only occurred
in the brains of the mice and no teratomas were found.
Another interesting finding was that the immunostaining
was GFAP negative and Iba-1 negative, which meant
Muse cells did not differentiate into astrocytes or
microglia. Muse cells mainly differentiated into the
injured target cells, neurons, according to the microenvironment. This study indicated the Muse cells’
therapeutic potential for lacunar stroke.
In another study, SCID mice were subjected to
permanent middle cerebral artery occlusion, according
to the ischemic stroke model [33]. Muse cells and
non-Muse cells were transplanted into the ipsilateral
striatum 7 days after the onset of stroke. 42 days after
transplantation, the immunostaining results showed
that 45.3% ± 13.9% of GFP+ Muse cells were Tuj-1+,
20.5% ± 8.7% were NeuN+, and 1.4% ± 1.2% were
GFAP+, which corresponded with the Dezawa lab’s
research. Muse cells mainly differentiated into neurons
not astrocytes to regenerate injured tissue, while
non-Muse cells did not survive for 42 days. In the
Muse group, functional recovery was apparent 35 days
post-transplantation.
Both studies above demonstrated that non-Muse
cells could secrete nutrition factors to immunomodulate,
but they could not remain long-term in vivo to replace
injured cells. Contrastingly, Muse cells spontaneously
differentiated into target cells according to the microenvironment and recovered the host’s function.
3.3 Muse cells were highly effective in treating
ICH
In Hiroki Ohkuma’s experiment, GFP+ Muse cells
derived from human bone marrow MSC were injected
into the left putamen of SCID mice five days later
than the ICH modeling [34]. 69 days post-injection,
immunostaining results showed that 57.3% ± 3.5%
Journal of Neurorestoratology

Journal of Neurorestoratology

were NeuN+, 41.6% ± 4.7% were MAP-2+, and none
were GFAP+. In the water maze and motor function
tests, the scores in the Muse-engrafted group were
significantly higher than those in the non-Museengrafted group. No teratomas were found in either
group. This study demonstrates that Muse cells can
be used to treat ICH.
3.4 Muse cells and spinal cord injury
Xue Chen reported a partition-type tubular scaffold
for spinal cord injury repair [35]. The scaffold was
designed to match the anatomical features of the
T8-10 spinal cord of the rat, and it included chitosan
with platelet-derived growth factor (PDNF). Results
showed that this scaffold was suitable biocompatibility
towards Muse-NPCs (Muse-neural progenitor cells)
and could promote the directional migration and
growth of these cells. This in vitro study indicated
that the combination of a tubular scaffold, PDGF and
Muse-NPCs may be a promising model for spinal
cord grafts in vivo.
To explore the treatment of Muse cells in spinal cord
injury, we initially transplanted human umbilical cord
MSCs-Muse cells into contused Sprague-Dawley rats’
spinal cords. 4 weeks post-transplantation, Muse cells
survived and migrated into the injury site from four
injection sites around the injury area. Moreover, we
successfully induced Muse cells into neural spheres
and they were Nestin positive. As it needs millions of
mesenchymal stromal cells to sort out enough Muse
cells for transplantation [5, 36], we also developed a
systemic culturing method to obtain millions of Muse
cells quickly and efficiently by MACS (unpublished
data). We are confident that Muse cell therapy would
benefit spinal cord neural regeneration.

4

Clinical research of Muse cells in
Neurorestoratology

4.1

Muse cells in acute stroke patients

Dr. Satoshi Kuroda enrolled 29 acute stroke patients
and 5 normal healthy persons to evaluate the number
trending of Muse cells in the peripheral blood after
ischemic stroke [37]. Results showed that the number
of Muse cells was 3.5 ± 4.3 cells/μL in the peripheral
blood of healthy persons. But in the stroke patient
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group, the number of Muse cells sharply increased
to 81.9 ± 78.0 cells/μL after 24 hours. The number of
Muse cells dropped slowly to 68.7 ± 64.9 cells/μL 30 days
later, but this change was not significant. Further
multivariate factor analysis revealed smoking and
alcohol consumption were two independent factors
that affected the level of Muse cells. Another 8 cadavers
analysis indicated that the percentage of Muse cells
was 0.20% ± 0.17% in bone marrow and decreased
with aging. This study showed that Muse cells were
mobilized from the bone marrow into peripheral
blood in the acute stage of ischemic stroke. Increasing
endogenous Muse cells or exogenous administration
of Muse cells may recover patients’ function after
ischemic stroke.
4.2 Clinical trials of Muse cells
Since Muse cells are non-tumorigenic and account
for a part of MSCs, which are already widely used in
clinical trials, they are feasible for clinical trials from
the viewpoint of safety. Besides, many preclinical
studies also demonstrate Muse cells are safe and
effective in vivo. Although there are no related clinical
trials in Neurorestoratology field, a phase I clinical trial
to evaluate Muse cell application for the treatment of
acute myocardial infarction has been initiated in Japan
by Mari Dezawa [30]. After verification of the safety
of Muse cell administration, the range of application
will be expanded.

5

Future of Muse cells

Muse cells may be the real stem cells in mesenchymal
stromal cells.
The concept of “mesenchymal stem cells” dated back
to 1991 when US biologist Arnold Caplan claimed to
isolate a type of stem cell found in bone marrow [38].
Over the next decades, the number of reported tissue
types containing “mesenchymal stem cells” exploded.
Studies also suggested that these cells could differentiate into cells of all three lineages. During this period,
researchers confused the concepts “mesenchymal
stem cells” and “mesenchymal stromal cells”. So International Society for Cellular Therapy (ISCT) believes
that “mesenchymal stem cells” are not really stem
cells. Naming them as “mesenchymal stromal cells”
is more rational. Then ISCT made the standard of
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identification of “mesenchymal stromal cells” [39–41].
In the past few years, there has been questioning of
“mesenchymal stem cells” as a valid biological entity
[42]. Many authors reported that after in vivo transplantation, no more than 3% of “mesenchymal stem
cells” could survive and few could differentiate into
functional cells, especially in the Neurorestoratology
field [23, 43]. Last year, Caplan declared that he no
longer believes that “mesenchymal stem cells” are
stem cells [44]. Huang also appealed to use the name
correctly [45]. Douglas Sipp declared the existence
of a tissue-specific stem cell in bone-marrow stroma,
albeit one with a limited ability to differentiate into
other cell types [42]. Muse cells are a subpopulation
of mesenchymal stromal cells, accounting for about
0.01%–3% [13]. They portray the stemness characteristics
as described above, and Muse cells may be the real
stem cells in mesenchymal stromal cells. The future
of Muse cells is bright.

6

Summary: Muse cells may revolutionize
regenerative medicine

Cell therapy is well known as the most promising
treatment in regenerative medicine. Embryonic stem
cells, induced pluripotent stem cells, neural stem cells
and other functional cells, such as Schwann cells have
been demonstrated effectiveness in treating certain
diseases. However, these cell groups face barriers in
cell source, ethics, tumorigenicity or limited functional
recovery [46]. Studies have shown that Muse cells
could migrate to and home into damaged areas by
intravenous (IV) injection [22, 31, 47–52], which makes
them practical for regenerative therapy. Only three
steps are necessary for Muse cell transplantation. First
Muse cells are isolated from mesenchymal stromal
cells derived from bone marrow, fat or umbilical cords.
The second step is Muse cell expansion. Finally, Muse
cells are injected into patients by IV. Allogenic Muse
cell function mimics autologous cell function, and
differentiation does not need to be induced. As a
result, Muse cells spontaneously differentiate into target
cells after homing. As naturally existing stem cells,
Muse cells may revolutionize regenerative medicine.
More basic research and high-quality studies, such as
multicenter, random, double blind, and placebo-control
clinical trials need to be carried out.
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